UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce.
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho